Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled Trial
研究概览
详细说明
Background: Although bismuth is not an antibiotic, it enhances antibiotic efficacy through multiple synergistic mechanisms. Currently, it remains unknown whether adding bismuth to a 14-day bismuth-vonoprazan-amoxicillin triple therapy is superior or non-inferior to the vonoprazan-amoxicillin dual therapy alone.
Objectives: This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based triple therapy versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication.
Hypothesis: The investigators hypothesize that the efficacy of a 14-day bismuth-vonoprazan triple therapy is superior or non-inferior to that of a 14-day vonoprazan-based dual therapy without bismuth.
Methods:
Study Design: An open-label, randomized controlled trial (RCT). Participants: The investigators intend to recruit 990 treatment-naïve patients with confirmed H. pylori infection.
Intervention and Randomization: Eligible participants will be randomized into one of two groups:
- Group A: 14-day bismuth-vonoprazan triple therapy.
- Group B: 14-day vonoprazan-based dual therapy (without bismuth).
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Mei-Jyh Chen, MD, PhD
- 电话号码:886-2-23123456 Ext. 265427
- 邮箱:migichen@ntuh.gov.tw
学习地点
-
-
-
Taipei、台湾
- 招聘中
- National Taiwan University Hospital
-
接触:
- Mei-Jyh Chen, MD
- 电话号码:886-2-23123456 Ext. 63541
- 邮箱:migichen@ntuh.gov.tw
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Individuals infected with Helicobacter pylori who have not previously undergone eradication therapy.
- Individuals willing to receive first-line eradication therapy.
- Study participants must be 20 years of age or older.
Exclusion Criteria:
- Individuals with a history of gastrectomy (stomach removal surgery).
- Individuals unsuitable to receive the study drug (e.g., history of allergy or severe adverse effects to the study drug).
- Pregnant or breastfeeding women.
- Individuals with severe acute or chronic diseases, such as renal failure, liver cirrhosis, or incurable malignant tumors.
- Patients with chronic hepatitis (AST [Aspartate Aminotransferase] or ALT [Alanine Aminotransferase] > 100 U/L).
- Individuals unwilling to comply with the treatment plan or sign the informed consent form.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Bismuth Add-on to Vonoprazan Dual Therapy
14-day bismuth-vonoprazan-amoxicillin triple therapy
|
bismuth, vonoprazan and amoxicillin for 14 days
|
|
有源比较器:Vonoprazan Dual Therapy
14-day vonoprazan-based dual therapy (without bismuth).
|
vonoprazan and amoxicillin for 14 days
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Eradication rate determined by Intention-to-Treat (ITT) analysis
大体时间:6-8 weeks
|
Eradication rate will be determined by urea breath test at least 6 weeks later after completion of treatment.
|
6-8 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Per-protocol (PP) eradication rate; adverse event profiles
大体时间:6-8 weeks
|
Eradication rate will be determined by urea breath test at least 6 weeks later after completion of treatment.
A standard interview and questionaire will be used toassess the adverse effects.
|
6-8 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 202602016MINC
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.